Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV.

Br J Cancer. 2015 Mar 31;112(7):1199-205. doi: 10.1038/bjc.2015.73.

2.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

3.

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.

Keyvanjah K, DePrimo SE, Harmon CS, Huang X, Kern KA, Carley W.

J Transl Med. 2012 Aug 16;10:165. doi: 10.1186/1479-5876-10-165.

4.

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG.

Clin Cancer Res. 2012 Jun 1;18(11):3170-9. doi: 10.1158/1078-0432.CCR-11-3005.

5.

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.

Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ.

Ann Oncol. 2012 Mar;23(3):688-94. doi: 10.1093/annonc/mdr349. Epub 2011 Aug 5.

6.

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S.

J Transl Med. 2011 Jul 25;9:120. doi: 10.1186/1479-5876-9-120.

7.

Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.

Am J Clin Oncol. 2010 Dec;33(6):614-8. doi: 10.1097/COC.0b013e3181c4454d.

PMID:
20142724
8.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.

Clin Cancer Res. 2009 Sep 15;15(18):5869-77. doi: 10.1158/1078-0432.CCR-08-2480. Epub 2009 Sep 8.

9.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.

Eur J Cancer. 2009 Jul;45(11):1959-68. doi: 10.1016/j.ejca.2009.02.011. Epub 2009 Mar 11.

PMID:
19282169
10.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

PMID:
18669461
11.

Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia.

Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC.

Cardiovasc Res. 2003 Jul 1;59(1):143-51.

PMID:
12829185
14.
17.

Protein kinase C inhibits human hair follicle growth and hair fibre production in organ culture.

Harmon CS, Nevins TD, Bollag WB.

Br J Dermatol. 1995 Nov;133(5):686-93.

PMID:
8555017
18.

Biphasic effect of 1,25-dihydroxyvitamin D3 on primary mouse epidermal keratinocyte proliferation.

Bollag WB, Ducote J, Harmon CS.

J Cell Physiol. 1995 May;163(2):248-56.

PMID:
7706369
19.
21.

Regulation of fos-lacZ fusion gene expression in primary mouse epidermal keratinocytes isolated from transgenic mice.

Bollag WB, Xiong Y, Ducote J, Harmon CS.

Biochem J. 1994 May 15;300 ( Pt 1):263-70. Erratum in: Biochem J 1995 Mar 15;306(Pt 3):879.

22.

Hair fibre production by human hair follicles in whole-organ culture.

Harmon CS, Nevins TD.

Br J Dermatol. 1994 Apr;130(4):415-23.

PMID:
8186105
23.

IL-1 alpha inhibits human hair follicle growth and hair fiber production in whole-organ cultures.

Harmon CS, Nevins TD.

Lymphokine Cytokine Res. 1993 Aug;12(4):197-203.

PMID:
8218592
24.
25.
26.

Making new employees an integral part of the team.

Harmon CS, Lichtman M, Parker R, Hallas G.

Contemp Longterm Care. 1992 Aug;15(8):24, 70. No abstract available.

PMID:
10121213
27.

Barrier function of human keratinocyte cultures grown at the air-liquid interface.

Mak VH, Cumpstone MB, Kennedy AH, Harmon CS, Guy RH, Potts RO.

J Invest Dermatol. 1991 Mar;96(3):323-7.

28.

The water permeability of primary mouse keratinocyte cultures grown at the air-liquid interface.

Cumpstone MB, Kennedy AH, Harmon CS, Potts RO.

J Invest Dermatol. 1989 Apr;92(4):598-600.

29.
30.

Effect of ischemia and reperfusion of pig skin flaps on epidermal glycogen metabolism.

Harmon CS, Masser MR, Phizackerley PJ.

J Invest Dermatol. 1986 Jan;86(1):69-73.

32.

Glycogen metabolism in psoriatic epidermis and in regenerating epidermis.

Harmon CS, Phizackerley PJ.

Clin Sci (Lond). 1984 Sep;67(3):291-8.

PMID:
6432401
33.

The effects of starvation and re-feeding on glycogen metabolism in mouse tail skin.

Harmon CS, Phizackerley PJ.

Biochem J. 1983 Jun 15;212(3):679-83.

34.

Glucose metabolism in experimental skin flaps.

Cohen BE, Harmon CS, Phizackerley PJ.

Plast Reconstr Surg. 1983 Jan;71(1):79-86.

PMID:
6849026
35.

Inhibition by parathyroid hormone of glycogen synthesis in the perfused rat liver.

Hems DA, Harmon CS, Whitton PD.

FEBS Lett. 1975 Oct 15;58(1):167-9. No abstract available.

Supplemental Content

Loading ...
Support Center